Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal.  All content is subject to the portal’s Community Content Guidelines.

 


What FDA's INTERACT Feedback Means for the CMC Pathway

Glafabra
Posted at Sep 14

FDA's written INTERACT feedback (following the July 16 meeting) noted our nonclinical data support a proposed early, exploratory clinical study, recommended plasma lyso-Gb3 as the primary pharmacodynamic readout, endorsed at least two years of eGFR follow-up, and confirmed CMC knowledge (vector backbone, packaging system, process steps) can be leveraged across Glafabra's Fabry, Pompe, and Gaucher ...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

The Clinical Data Dilemma: Balancing Speed and Credibility in Communicating Early-Stage Life Science Clinical Results

Ray Jordan Ray Jordan
Posted at Sep 12

Prepared by Putnam Insights LLC

For any early-stage bio- or med-tech company, the arrival of initial positive clinical data presents an immediate dual challenge.

First, there is the fundamental need to establish a highly credible, enduring platform for your science. To gain traction with medical opinion leaders and regulatory bodies, the data must eventually live in a respected, peer-reviewed medi...more

Categories: Educational Content  |  Featured  |  General Life Sciences

What 'Testing the Waters' Actually Means

Glafabra
Posted at Sep 11

Testing the Waters is a formal SEC mechanism under Regulation Crowdfunding that lets a company gauge investor interest before filing a formal offering statement (Form C). No money can be solicited or accepted at this stage, and no offer to buy securities can be made.

That's why every post here carries the full disclosure below, and why registering interest is non-binding -- it's a real, if informa...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

What the Five-Year FACTS Data Does — and Does Not — Show

Glafabra
Posted at Sep 9

In the FACTS trial (5 patients, Canada, NCT02800070): a 48% reduction in plasma lyso-Gb3 vs. no-ERT baseline (p<0.0001) at 5-year follow-up; 4 of 5 patients below the lyso-Gb3 threshold at year 5; all 5 maintained durable enzyme expression; zero product-attributable serious adverse events; polyclonal integration with no clonal dominance.

This shows the approach can produce a durable biomarker r...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

What Changed After the First Two Campaign Months

Glafabra
Posted at Sep 7

Two months of daily public content. Here's the honest read.

Engagement grew meaningfully once we started introducing the team behind Live-cel and reacting to real industry news, rather than only running scheduled educational content. Our DECODE education series also moved from a manual answer-in-comments format to an integrated Q&A format, based on direct reader feedback.

None of this changes ...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

Two Months, One Platform, Three Diseases: Glafabra's Progress So Far

Glafabra
Posted at Sep 5

Two months. One platform. Three diseases. Building in public the whole way.

Fabry, Pompe, and Gaucher disease — three diseases the platform is designed to address by correcting one cell type and swapping in the disease-specific gene. An FDA meeting behind us, an IND protocol taking shape, University of Utah Health planned as the clinical site, and a Japan strategy running in parallel from day one.

...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

Two Months Into Testing the Waters: What's Ahead for Glafabra

Glafabra
Posted at Sep 4

Two months of Testing the Waters, almost to the day.

Since June 22: 18 questions answered through DECODE, four members of the Glafabra team introduced in person on LinkedIn, and a real-time record of an FDA meeting, a protocol taking shape, and a Japan strategy moving in parallel with the U.S. one.

What's ahead: more team introductions, continued DECODE questions, and whatever comes out of IFFD an...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

How Common Is Fabry Disease? — DECODE No. 18

Glafabra
Posted at Sep 3

(Answer to the question last time on August 31: hands and feet — acroparesthesia, caused by small-fiber nerve involvement, often starting in childhood.)

Fabry disease is rare, but estimates for exactly how rare span a wide range — and most researchers think the real number is higher than any of them.

Roughly how many people are estimated to be born with Fabry disease? Drop your guess in the commen...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags: